Taysha Gene Therapies (TSHA) Stock
Clinical gene therapy developer for neurological and rare diseases. Here's the price, business snapshot, and what's worth knowing about Taysha Gene Therapies in October 2026.
Taysha Gene Therapies Inc (TSHA) is a clinical-stage biotechnology company developing gene therapies for neurological and rare genetic disorders. With a market capitalisation of about $1.40 billion, Taysha focuses on delivering adeno-associated virus (AAV)‑based treatments designed to address root causes rather than symptoms. Investors should note the company is largely driven by clinical trial progress, regulatory milestones and potential partnerships or licensing deals. Like many gene‑therapy developers, Taysha faces binary outcome risk from trial results, significant research and development costs, and potential dilution if additional capital is required. That said, success in trials or a favourable regulatory path could meaningfully re‑rate the business. This summary is educational only and not personal financial advice; investors should consider their risk tolerance, investment horizon and seek independent advice before acting.
Taysha Gene Therapies (TSHA) Stock Forecast
Analyst price target, next 12 months
$10.18
+155.7% vs today's $3.98
Price range over the last 12 months
Close to its 12-month low
Analysts covering Taysha Gene Therapies have a consensus 12-month target of $10.18, above the current price of $3.98.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying TAYSHA Gene Therapies stock with a target price of $10.18, indicating strong growth potential.
Financial Health
Taysha Gene Therapies is generating modest revenue and cash flow, but faces challenges in growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical programmes progress
Taysha’s value largely depends on trial outcomes and regulatory milestones, which can create opportunity but also binary downside risks.
Catalyst‑driven moves
Share price may react strongly to news such as trial readouts, partnerships or licensing deals, though performance can be volatile.
Manufacturing & access
Scaling gene‑therapy manufacturing and securing market access are crucial for long‑term value; these areas carry technical and commercial risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
